Cassava Sciences reported a net loss of $6.3 million for the full year 2020, with cash and cash equivalents at $93.5 million as of December 31, 2020. The company is on track to initiate two pivotal Phase 3 studies in the second half of 2021 and expects net cash use of $20 to $25 million in 2021.